PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.7500
-0.0180 (-2.34%)
At close: Mar 28, 2025, 4:00 PM
0.7203
-0.0297 (-3.96%)
After-hours: Mar 28, 2025, 5:27 PM EDT
PAVmed Revenue
In the year 2024, PAVmed had annual revenue of $3.00M with 22.15% growth. PAVmed had revenue of $10.00K in the quarter ending December 31, 2024, a decrease of -99.05%.
Revenue (ttm)
$3.00M
Revenue Growth
+22.15%
P/S Ratio
2.42
Revenue / Employee
$27,991
Employees
107
Market Cap
12.59M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PAVM News
- 3 days ago - Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PRNewsWire
- 5 days ago - PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 days ago - Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 10 days ago - Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening - PRNewsWire
- 12 days ago - Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PRNewsWire
- 17 days ago - Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - PRNewsWire
- 20 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - PRNewsWire